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Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers,  chemotherapy 
or hormone therapy alone does not result in satisfactory tumor response,  it is unknown whether con-
current chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes.  We con-
ducted a randomized phase II trial to test the responses of ER-positive patients to concurrent adminis-
tration of chemo-endocrine therapy in the neoadjuvant setting.  Women with stage II-III,  ER-positive,  
invasive breast cancer (n=28) received paclitaxel followed by ﬂuorouracil,  epirubicin,  cyclophosph-
amide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of 
goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for post-
menopausal women.  The primary endpoint was the pathological complete response (pCR) rate after 
neoadjuvant therapy.  Twenty-eight patients were randomized.  There were no signiﬁcant diﬀerences 
in pCR rate between the concurrent group (12.5ｵ; 2/16) and the chemotherapy alone group 
(8.3ｵ; 1/12).  Tumor size after therapy was signiﬁcantly reduced in the concurrent therapy group 
(p=0.035),  but not in the chemotherapy-alone group (p=0.622).  Neoadjuvant chemotherapy with concur-
rent hormone therapy provided no signiﬁcant improvement in pCR rate in ER-positive breast cancers.  
These preliminary results should be followed up by further studies.
Key words: breast cancer,  neoadjuvant chemotherapy,  concurrent hormone therapy,  estrogen receptor posi-
tive,  tumor response
eoadjuvant chemotherapy (NAC) has become 
standard clinical practice for the treatment of 
breast cancer.  Results from a large randomized trial 
showed that overall survival (OS) and disease-free 
survival (DFS) in patients with early breast cancer 
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did not depend on whether chemotherapy was given in 
the neoadjuvant or adjuvant setting [1].  Higher rates 
of pathological complete response (pCR) have been 
reported in triple-receptor-negative breast cancers,  
human epidermal growth factor receptor 2 (HER2)-
positive breast cancers,  high-grade breast cancers,  
and breast cancers in younger women [2-6].  Higher 
pCR rates were also associated with breast cancers 
with a high recurrence score.  For breast cancers that 
are strongly ER-positive the beneﬁt in terms of patho-
logical complete response is limited.  [5,  7].  
However,  neoadjuvant chemotherapy has become 
standard therapy for breast cancers with high risk for 
recurrence.  Novel strategies are needed to improve 
the overall tumor response in ER-positive patients and 
the high-recurrence-risk group,  such as those with 
lymphatic tumor emboli (＋).  Traditionally,  neoadju-
vant endocrine therapy has been reserved for locally 
advanced breast cancers,  often in older patients with 
co-morbidities.  However,  in recent times several 
clinical trials have examined this approach in patients 
with operable breast cancer and have demonstrated the 
feasibility of this low-toxicity approach in postmeno-
pausal women [8-12].
　 Whether to add chemotherapy to endocrine therapy 
is attractive in theory [13],  but there is no consensus 
regarding tamoxifen as well as other selective estro-
gen receptor modulators (SERMs) [14].  Previous 
clinical studies have found that concurrent tamoxifen 
and chemotherapy resulted in inferior outcomes com-
pared to the sequential therapy [14-18].  Moreover,  
interference with drug-induced cytotoxicity has been 
found in vitro when tamoxifen is added to cancer cell 
lines concurrently with chemotherapy [15,  19,  20].  
As a result of these studies,  concurrent chemotherapy 
and tamoxifen therapy are avoided.  Recent preclinical 
data by Tabuchi et al.  have also shown that Bcl-2 
overexpression through an ER-mediated pathway by 
E2 treatment caused resistance to paclitaxel in 
ER-positive breast cancers [21].  However,  Ikeda et 
al.  showed the synergistic eﬀects of aromatase inhibi-
tor (AI) with chemotherapy,  in contrast to the antago-
nistic eﬀects of tamoxifen with chemotherapy [22],  
and Sui et al also reported that the addition of fulves-
trant could completely reverse the resistance of 
ER-positive cells to paclitaxel,  vinblastine and vinore-
lbine [23,  24].  They hypothesize that a combination 
of a cytotoxic and an endocrine agent could have syn-
ergistic eﬀects in ER-positive cancers.  
　 To examine this hypothesis,  we conducted this trial 
in the neoadjuvant setting to assess the eﬃcacy of 
concurrent estrogen deprivation therapy and chemo-
therapy for ER-positive cases.
Materials and Methods
　 Patient cohorts. The study was conducted at 5 
referral hospitals including Chugoku Central Hospital,  
Okayama University Hospital,  Hiroshima City 
Hospital,  Onomichi City Hospital,  and Okayama 
Central Hospital.  To be eligible,  patients had to beｧ
20 years of age,  ECOG performance status 0 or 1,  
histologically conﬁrmed invasive breast cancer with a 
clinical stage of T1-4,  N0-3,  and they had to have 
received no treatment for the current breast cancer.  
A prior history of hormone replacement therapy was 
allowed,  provided it had been discontinued 6 months 
before the diagnosis of the current breast cancer.  
Patients were excluded if they were pregnant or 
breast feeding,  had a history of severe allergic reac-
tions,  an allergy to the surfactant cremophor,  pacli-
taxel (T),  5-ﬂuorouracil (F),  epirubicin (E),  cyclo-
phosphamide (C),  LHRH analogues,  exemestane,  or 
alcohol.  Patients were also excluded if they had mul-
tiple active malignancies.  
　 Pretreatment core-needle-biopsy specimens and 
surgical specimens of the primary cancer after neoad-
juvant therapy alone were collected between April 
2007 and March 2009; then the period of enrollment 
was extended due to low numbers of patients.  The 
study was approved by the Institutional Review Board 
at each institution and all patients signed an informed 
consent before therapy.  The study was a neoadjuvant 
phase II randomized multicenter clinical trial 
(NACED: UMIN000000748,  http://www.umin.ac.jp/) 
in ER-positive breast cancer to assess the eﬃcacy of 
estrogen deprivation therapy through the concurrent 
administration of chemotherapy plus a luteinizing 
hormone-releasing hormone (LHRH) analogue in pre-
menopausal women or an aromatase inhibitor in post-
menopausal women versus chemotherapy alone.
　 Histopathology and scoring of biomarkers.
We obtained core-needle-biopsy specimens before 
therapy (i.e.,  at baseline) and excision samples at 
surgery.  Modiﬁed Blackʼs nuclear grades were used 
(grades 1 to 3).  ER and Progesterone receptor (PR) 
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status was classiﬁed according to the Allred score or 
immunohistologically (IHC).  For Allred scores 3-8 or 
in IHC [25],  having＞10 percent positive tumor cells 
is described as positive.  HER2 was scored by Hercep 
Test (DAKO Glostrup Denmark),  using a 0-3 scale,  
based on the staining intensity of tumor cells.  Cases 
that showed either staining score 3 or HER2 gene copy 
number＞2.0 by ﬂuorescent in situ hybridization 
(FISH) analysis were considered HER2-positive as per 
ASCO guidelines [26,  27].  Immunohistochemical 
(IHC) staining for Ki67 was used to establish a prolif-
eration index and was assessed pre- and post-neoadju-
vant therapy.  The IHC-Ki67 assay was performed 
using the MIB-1 antibody (DAKO Glostrup Denmark) 
on the Immunostainer system (DAKO Glostrup 
Denmark).  To score Ki67,  photomicrographs were 
taken under 40×magniﬁcation and the percentage of 
Ki67-positive cells was scored.  Where possible,  
1,000 malignant cells (at least 500 cells) in the inva-
sive carcinoma cells area were viewed.  
　 Residual disease (RD) after neoadjuvant therapy 
includes a broad range of actual responses from near 
pCR to no change in the size of the tumor to outright 
resistance to treatment.  For evaluation of the 
response to chemotherapy with or without endocrine 
therapy we calculated RCB,  which is a validated sig-
niﬁcant predictor of disease-free survival after neoad-
juvant chemotherapy [28].  We obtained the patho-
logical variables (the bidimensional diameters of the 
primary tumor bed in the resection specimen,  the 
proportion of the primary tumor bed that contains 
invasive carcinoma,  the number of metastatic axillary 
lymph nodes and the diameters of the largest meta-
static axillary lymph nodes) and entered these data into 
the online RCB tool (http://www.nuverabio.com/
other/rcb/rcbIndex.html accessed date: April,  2011).  
The RCB index was classiﬁed into RCB-0,  I,  II and 
III.  An RCB index of 0 (＝pCR) contains no invasive 
or in situ disease in the breast or axillary lymph 
nodes.  
　 Treatment. All patients received 80mg/m2 of 
paclitaxel (T) given weekly for 12 weeks followed by a 
combination of ﬂuorouracil (F) 500mg/m2,  epirubicin 
(E) 100mg/m2 and cyclophosphamide (C) 500mg/m2 
(FEC) given every 3 weeks for 4 cycles.  
Premenopausal women were randomized to receive 
chemotherapy alone or chemotherapy plus a subcuta-
neous injection (3.75mg) of the LHRH analogue,  
LEUPLIN® (Takeda; Osaka,  Japan) every 28 days 
for 6 months,  beginning within 2 weeks of the ﬁrst T 
treatment.  Postmenopausal women were randomized 
to receive chemotherapy alone or chemotherapy plus 
25mg daily of a steroidal AI,  exemestane,  initiated 
within 2 weeks of the ﬁrst T for 6 consecutive months 
until one day before operation.  
　 Toxicity and tumor measurements were recorded 
during each cycle of therapy.  Adverse events were 
recorded using Common Terminology Criteria for 
Adverse Event (CTCAE) version 3.0 or 4.0.  
Treatment was discontinued if severe toxicity was 
reported as probably or deﬁnitely related to treat-
ment,  or if the patients withdrew consent.
　 Statistical analysis. The primary objective of 
the study was to compare the pCR rates after neoad-
juvant chemotherapy between neoadjuvant chemother-
apy alone and that in combination with concurrent 
estrogen-deprivation treatment by either an LHRH-
agonist or AI in patients with ER-positive breast 
cancer.  The planned number of cases was 120 based 
on the Bayesian method with an 80ｵ conﬁdence level 
and 15ｵ margin of error [29].  The two secondary 
endpoints were tumor response,  determined by change 
in tumor size as assessed by calipers or ultrasound,  
and histopathological response as assessed by change 
in IHC-Ki67 and RCB [28].  Because clinical out-
comes in ER-positive cancers are distinct by prolif-
erative level,  we assessed the eﬃcacy by proliferative 
level,  and divided the ER-positive cohort into high- 
and low-IHC-Ki67 groups (cutoﬀ point for IHC-Ki67 
level,  13.25ｵ,  as previously described by Cheang et 
al.  [30]).  Statistical analyses were performed with R 
version 2.10.0 (http://www. r-project. org/ accessed 
date: October,  2011).  For continuous variables we 
used the Wilcoxon test and for categorical variables 
we used the Fisher exact test.  Two-sided p-values
＜0.05 were considered statistically signiﬁcant.
Results
　 In the original plan,  we set the target sample size 
as 120 cases in 2 years.  The accumulated cases had 
not reached this number in 2 years,  so we decided to 
extend the study for another 2 years.  Although we had 
also set an interim analysis at the time that 60 cases 
were enrolled,  this number of cases was never 
reached,  so the early step was skipped.  A total of 31 
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patients were enrolled between April 2007 and March 
2011 (14 patients from Chugoku Central Hospital,  13 
from Okayama University Hospital,  2 from Hiroshima 
City Hospital,  1 from Onomichi City Hospital and 1 
from Okayama Central Hospital).  Patients and disease 
characteristics are presented in Table 1.  There were 
no signiﬁcant diﬀerences in the patient age,  clinical T 
and N stages,  ER,  PR,  HER2 and menopausal status 
between the treatment groups.  Twenty-eight patients 
fully completed the protocol-speciﬁed therapy.  One 
patient withdrew because of grade 3 interstitial pneu-
monia,  and 2 patients withdrew consent.  One patient 
required a dose reduction of epirubicin.  Ultimately,  
16 patients (57.1ｵ) received the concurrent therapy,  
of whom 9 were premenopausal (32.1ｵ) and 7 were 
postmenopausal (25.0ｵ),  while twelve patients (42.9ｵ) 
received chemotherapy only (7 were premenopausal 
and 5 were postmenopausal).  Following completion of 
neoadjuvant therapy,  all patients proceeded to surgi-
cal resection of their breast cancers.  Of 14 patients 
(50.0ｵ) considered ineligible for breast-conserving 
surgery at baseline,  6 (42.9ｵ) were able to undergo 
achieved breast-conserving surgery and 8 (57.1ｵ) 
underwent mastectomy.  Of the 6 patients with breast-
conserving surgery,  4 (66.7ｵ) received the concur-
rent therapy and 2 (33.3ｵ) received chemotherapy 
only.  The remaining 14 patients (50.0ｵ) underwent 
breast-conserving surgery as planned at presentation.  
　 pCR rate after neoadjuvant treatment.
First,  we assessed pCR rates in 2 groups after neo-
adjuvant treatment,  and there were no signiﬁcant dif-
ferences (p＝1.000) between concurrent chemo-endo-
crine therapy (pCR rate: 12.5ｵ (=2/16),  and 
chemotherapy alone (8.3ｵ (=1/12)).  
　 Change in tumor size between pre and post 
neoadjuvant treatment. Second,  we assessed 
overall tumor response by change in tumor size 
between pre- and post-neoadjuvant therapy.  Nine 
cases (32.1ｵ) showed progressive disease in spite of 
neoadjuvant therapy,  including 5 (31.3ｵ: 5/16) with 
concurrent therapy and 4 (33.3ｵ: 4/12) with chemo-
therapy alone.  Fig.  1 shows the change in tumor size 
between pre- and post-therapy in 2 regimens; tumor 
size after therapy was signiﬁcantly reduced in the 
concurrent therapy group (p＝0.035),  but not in the 
chemotherapy-alone group (p＝0.622).  In the concur-
rent group,  there was a marginally signiﬁcant tumor 
response in the high-Ki67 group (p＝0.067),  but not in 
the low-Ki67 group (p＝0.356).  In the chemotherapy-
only group,  both Ki67 groups (high and low Ki67 
level) had no signiﬁcant diﬀerences in tumor size.      
　 Measurement of histopathological response.
Next,  we assessed histopathological response by 
change in IHC-Ki67 level and RCB in the 2 diﬀerent 
neoadjuvant regimens.  In IHC-Ki67 analyses,  3 cases 
(10.7ｵ) that achieved pCR were excluded from the 
analysis,  because we could not evaluate the IHC-Ki67 
level after neoadjuvant therapy.  In the remaining 
cases a signiﬁcant decrease in the IHC-Ki67 level was 
observed between pre-treatment biopsies and excision 
specimens; however,  there was no statistically sig-
niﬁcant diﬀerence between the 2 treatment regimens 
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Table 1　 Patient Characteristics＊
Chemo＋Hormone Chemo p-value
Number of cases 16 12
Age (Median: mini.-max.) 48.6 (34-62) 49 (35-64) 0.944 
T at diagnosis (TNM)
　T1  3  1 0.453 
　T2 10 11
　T3  1  0
　T4  2  0
Nodal status at diagnosis
　Negative  8  8 0.459 
　Positive  8  4
Histologic grade
　1  1  2 0.687 
　2 13  8
　3  2  2
ER status
　positive 16 12 1.000 
　negative  0  0
PR status 
　positive 10 10 0.401 
　negative  6  2
Her2 status
　positive  4  1 0.355 
　negative 12 11
Menopus status
　pre  9  7 1.000 
　post  7  5
＊p-value for categorical value was calculated by Fisher exact 
test; p-value for continuous value was calculated by Wilcoxon test.
(Concurrent therapy,  p-value=0.005; Chemotherapy 
only,  p-value=0.021,  Fig.  2).  There were 2 cases 
(Concurrent group,  1; Chemotherapy group,  1) with 
a paradoxical increase of IHC-Ki67 level compared 
with pre-treatment status.  In the low-IHC-Ki67 group,  
the concurrent-therapy group had a signiﬁcantly 
decrease in IHC-Ki67 level (p-value＝0.003),  but the 
chemotherapy-only group did not (p-value＝0.147).  On 
the other hand,  in the high-IHC-Ki67 group,  both the 
concurrent-therapy and chemotherapy-only groups had 
relatively favorable decreases in tumor size 
(Concurrent: p-value＝0.084,  Chemo only: p-value＝ 
0.026).  
　 Finally,  we assessed RCB in the treatment groups.  
Of the 16 patients who received concurrent therapy,  
2 (12.5ｵ) achieved an RCB-0 (pCR),  11 (68.8ｵ) 
achieved RCB-II,  and 3 (18.8ｵ) achieved RCB-III.  
Of the 12 patients who received chemotherapy only,  1 
(8.3ｵ) achieved RCB-0 (pCR),  3 (25.0ｵ) achieved 
RCB-I,  7 (58.3ｵ) achieved RCB-II,  and 1 (8.3ｵ) 
achieved RCB-III (Table 2).  There was no signiﬁcant 
diﬀerence in the RCB index between the 2 treatment 
groups (p-value＝0.143,  Fig.  3).  When we assessed 
RCB by IHC-Ki67 level,  there were no signiﬁcant 
diﬀerences between 2 regimens in either the high- or 
low-IHC-Ki67 group.  
Discussion
　 We examined whether ER-positive breast cancer 
patients treated by concurrent administration of che-
motherapy plus an LHRH agonist or an AI beneﬁt 
diﬀerently from those receiving chemotherapy alone in 
the neoadjuvant setting.  pCR rates after neoadjuvant 
therapy in the 2 groups were not signiﬁcantly diﬀer-
ent.  Previous studies showed that the expected rate 
for pCR after neoadjuvant chemotherapy in 
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Fig. 1　 Two-way interaction plots for tumor size between pre- and post- neoadjuvant therapy.  Two-way interaction plots showed change 
in tumor size between pre- and post-neoadjuvant therapy.  P-value was calculated by paired match t-test.
Table 2　 RCB class in the treatment groups (No of Pt. )
RCB class Chemo＋Hormone Chemo only
0  2 1
I  0 3
II 11 7
III  3 1
ER-positive entities is lower than in ER-negative ones,  
and that ER-positive histology is a relative contraindi-
cation for neoadjuvant chemotherapy because the 
expected beneﬁt is modest because of less frequent 
clinical response [2-6].  In contrast to chemotherapy,  
neoadjuvant endocrine therapy is well tolerated,  with 
very few patients having to discontinue the treatment 
because of side eﬀects.  However,  the pCR rate for 
those given neoadjuvant endocrine therapy is not nec-
essarily satisfactory [8,  12].  In the preclinical level,  
Sui et al. [24] showed that the combination of anti-
estrogen agents such as fulvestrant might be a strat-
egy to reverse ER-mediated chemoresistance or sensi-
tize ER-positive breast tumors to chemotherapeutic 
296 Acta Med.  Okayama　Vol.  69,  No.  5Sugiu et al.
Chemo+Hormone (N=14) Chemo (N=11)
Pre treatment Post treatment Pre treatment Post treatment
IH
C
-K
i6
7 
le
ve
l
0
10
20
30
40
50
60
(%)
IH
C
-K
i6
7 
le
ve
l
0
10
20
30
40
50
60
(%)
All cases p=0.005
High Ki67 p=0.084
Low Ki67 p=0.003
All cases p=0.021
High Ki67 p=0.026
Low Ki67 p=0.147
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Fig. 3　 Box plots for RCB index according to 
neoadjuvant therapy regimens. Box plots show the 
RCB index level in 2 diﬀerent regimens (concurrent 
chemo-endocrine therapy and chemotherapy only). 
P-values were calculated by the Wilcoxon test.
agents.  Moreover,  Ikeda et al. [22] also reported that 
combination treatment with fulvestrant and various 
cytotoxic agents (paclitaxel,  docetaxel,  vinorelbine,  
and 5-ﬂuorouracil) has a synergistic eﬀect in 
ER-positive breast tumors.  Regarding chemoresistant 
factors,  Bcl-2 and microtubule-associated protein tau 
were downregulated by fulvestrant.  These studies 
used as the anti-estrogen agent fulvestrant,  which 
speciﬁcally binds to and destroys the ER,  blocking all 
estrogen activity,  unlike tamoxifen.  Unlike the pre-
clinical data,  we observed no signiﬁcant diﬀerence in 
the pCR rate for ER-positive breast cancers treated 
by concurrent chemo-endocrine therapy with exemes-
tane or an LHRH analogue,  and chemotherapy alone,  
indicating that giving concurrent therapy for 
ER-positive breast cancers in the neoadjuvant setting 
might not be as eﬀective as chemotherapy alone for 
achieving pCR.  
　 One of the reasons that our study did not show 
signiﬁcant beneﬁts from concurrent therapy might be 
the heterogeneity within ER-positive and HER2-
negative breast cancers [31].  ER-positive breast 
cancers do not beneﬁt equally from chemotherapy.  In 
past studies,  ER-positive tumors with high prolifera-
tion have shown a large chemotherapy beneﬁt,  while 
those with low and intermediate proliferation derived 
minimal,  if any,  beneﬁt from chemotherapy treatment 
[32].  Vaile et al. also reported the decreasing beneﬁt 
of chemotherapy with increasing ER expression,  indi-
cating the inadequacy of chemotherapy alone for 
patients with higher ER expression [33].  As in previ-
ous reports,  we showed that cases with high but not 
low Ki67 had signiﬁcant reduction in Ki67 level from 
chemotherapy alone (p-value＝0.026),  implying that 
ER-positive cases have distinct chemotherapy sensitiv-
ity according to Ki67 level,  and that we should select 
neoadjuvant regimens based on not only clinical stage,  
but also tumor characteristics.  More recent results 
indicate that Ki67 level might represent a valid sur-
rogate of outcome in patients with ER-positive breast 
cancer treated with neoadjuvant endocrine therapy.  In 
fact,  tumor Ki67 levels determined during neoadju-
vant endocrine treatment were found to be a marker of 
treatment eﬃcacy and to have a substantial prognostic 
value [34,  35].  In these studies,  reductions of Ki67 
level may represent good eﬃcacy from chemotherapy 
and/or hormone therapy and favorable clinical course.  
Our ﬁndings conﬁrmed similar signiﬁcant reduction of 
Ki67 level in both regimens (Concurrent: p-value＝ 
0.005,  Chemotherapy alone: p-value＝0.021),  indi-
cating that patients have similar favorable clinical 
outcomes in both regimens,  and the eﬀect of adding 
short-term hormone therapy on breast cancer progno-
sis may be limited.  Distinct subtypes of breast cancer 
may need distinct types of strategies.  The other pos-
sibility might come from the small sample size.  We 
could collect only 28 cases,  although we estimated a 
need for 120 cases to arrive at signiﬁcant diﬀerences 
between the 2 groups.  In future trials,  more precise 
estimations and better organization will be needed.    
　 Next,  we assessed residual disease after neoadju-
vant therapy in order to improve the prognostic 
information that can be obtained from evaluating 
pathologic response.  Symmans et al. [28] showed that 
RCB after neoadjuvant chemotherapy was indepen-
dently prognostic in a multivariate model that included 
various clinical and pathological covariates.  We 
showed similar RCB distributions in 2 distinct regi-
mens,  indicating again that administering concurrent 
hormone therapy of only short duration may not serve 
to improve breast cancer prognosis [36].  We also 
conﬁrmed the poor correlations between IHC-Ki67 
level and RCB index (Spearmanｾs rank correlation 
rho＝0.116,  data not shown).  The Ki67 level identi-
ﬁes cells in the G1/S and M phases of the cell cycle 
[37];  changes in Ki67 value,  indirectly assessing cell 
proliferation,  may be more appropriate at predicting 
the risk of recurrence in breast cancers,  as well to 
predict the magnitude of the chemotherapy beneﬁt in 
ER-positive breast cancers [32,  38] than the pCR 
rate,  which directly assesses carcinoma cell number 
and cellularity.  On the other hand,  RCB provides 
prognostic information from the primary tumor bed 
area,  overall cancer cellularity,  the percentage of 
cancer that is in situ disease,  lymph node inﬁltration,  
and diameter of largest metastasis [28].  By taking 
into consideration a broad range of actual responses 
from near pCR to outright treatment resistance,  RCB 
can identify patients with resistant disease more pre-
cisely than dichotomization of responses into pCR or 
RD.  The 2 biomarkers may be similar,  but they have 
diﬀerent predictive power for prognosis and provide 
diﬀerent prognostic information.
　 Our study has a number of limitations; primarily,  
the number of patients enrolled is too small.  
Furthermore,  the adequacy of an LHRH agonist in 
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suppressing ovarian function in premenopausal patients 
is uncertain.  It is also uncertain whether surrogate 
markers including IHC-Ki67 and RCB yield proper 
prognostic information after concurrent neoadjuvant 
chemo-endocrine therapy.  These could give rise to 
false discovery.  
　 Based on our ﬁndings,  the concurrent chemo-
endocrine therapy did not provide signiﬁcant diﬀer-
ences in pCR rates,  but provided signiﬁcant reduction 
of tumor size after neoadjuvant therapy in breast 
cancer patients with hormone receptor-positivity 
compared to chemotherapy alone.  
　 Based on our ﬁ ndings,  we cannot recommend rou-
tine administration of concurrent chemo-endocrine 
therapy in the clinical neoadjuvant setting.  A small 
subpopulation in ER-positive and HER2-negative cases 
may be suitable for concurrent therapy,  although we 
could not reveal it or identify any biomarkers to 
stratify.  These preliminary results should be followed 
up by further studies; however,  the neoadjuvant con-
current chemo-endocrine therapy approach should still 
be considered as investigational and should not be used 
outside a clinical trial.
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